Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

2.7K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
2.7K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.3K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.5K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.5K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison01:09

Peripherally and Centrally Acting Muscle Relaxants: A Comparison

4.8K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Humanized anti-P2X4 scFv reduces ATP-induced P2X4 currents and modulates excitability in human DRG neurons.

Molecular pain·2025
Same author

Humanized scFv Molecule Specific to an Extracellular Epitope of P2X4R as Therapy for Chronic Pain Management.

Cells·2025
Same author

Visceral pain-related acute actions of cerulein on mouse and human sensory neurons.

Molecular pain·2025
Same author

Neuroimmune mechanisms of a mouse model of chronic back pain.

bioRxiv : the preprint server for biology·2025
Same author

Role of HDAC5 Epigenetics in Chronic Craniofacial Neuropathic Pain.

International journal of molecular sciences·2024
Same author

In vivo imaging of cathepsin B in activated glia in the brain after orofacial formalin test.

Scientific reports·2024

Related Experiment Video

Updated: Mar 15, 2026

Assessment of Nerve Injury-Induced Mechanical Hypersensitivity in Rats Using an Orofacial Operant Pain Assay
07:39

Assessment of Nerve Injury-Induced Mechanical Hypersensitivity in Rats Using an Orofacial Operant Pain Assay

Published on: July 26, 2022

4.4K

Doxazosin Alleviates Chronic Orofacial Pain.

Karin N Westlund1,2, Bingye Xue1, Sabrina L McIlwrath1

  • 1Research Service, New Mexico VA Health Care System, Albuquerque, NM 87108, USA.

International Journal of Molecular Sciences
|March 14, 2026
PubMed
Summary

Doxazosin, an alpha-1 antagonist, reversed pain and anxiety in a rat model by modulating glial-neuronal interactions. This suggests a potential shift in noradrenergic system function from pain promotion to inhibition.

Keywords:
NAα1NAα2antioxidantanxietyhyperalgesiahypersensitivityneuronal-glial interactionnoradrenergicpain related behaviorsex differences

More Related Videos

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents
09:05

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents

Published on: January 10, 2014

8.0K
Chronic Constriction Injury of the Rat's Infraorbital Nerve IoN-CCI to Study Trigeminal Neuropathic Pain
10:52

Chronic Constriction Injury of the Rat's Infraorbital Nerve IoN-CCI to Study Trigeminal Neuropathic Pain

Published on: September 21, 2015

21.0K

Related Experiment Videos

Last Updated: Mar 15, 2026

Assessment of Nerve Injury-Induced Mechanical Hypersensitivity in Rats Using an Orofacial Operant Pain Assay
07:39

Assessment of Nerve Injury-Induced Mechanical Hypersensitivity in Rats Using an Orofacial Operant Pain Assay

Published on: July 26, 2022

4.4K
Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents
09:05

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents

Published on: January 10, 2014

8.0K
Chronic Constriction Injury of the Rat's Infraorbital Nerve IoN-CCI to Study Trigeminal Neuropathic Pain
10:52

Chronic Constriction Injury of the Rat's Infraorbital Nerve IoN-CCI to Study Trigeminal Neuropathic Pain

Published on: September 21, 2015

21.0K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Pain Research

Background:

  • The noradrenergic system, particularly alpha-2 (NAα2) and alpha-1 (NAα1) receptors, plays a dual role in pain processing.
  • Acute pain involves NAα2-mediated inhibition, while chronic pain can involve locus coeruleus-driven NAα1-mediated pain promotion.

Purpose of the Study:

  • To investigate the effects of a selective NAα1 receptor antagonist, doxazosin, on chronic inflammatory pain and associated behaviors.
  • To explore the underlying mechanisms, including glial activation and neurochemical changes, and potential sex differences.

Main Methods:

  • Utilized a rat model of chronic inflammatory trigeminal nerve compression (FRICT-ION).
  • Administered slow-release doxazosin to rats over a two-week period.
  • Assessed facial hypersensitivity, anxiety-like behaviors (elevated zero maze), cognitive function (novel recognition), and glial activation markers (cathepsin B, GFAP).

Main Results:

  • Doxazosin reversed facial hypersensitivity in both male and female rats.
  • Anxiety was reduced only in male rats, while novel recognition improved only in female rats.
  • Doxazosin decreased astrocytic activation in the somatosensory cortex and hippocampus, reducing glial-neuronal interactions and pain behaviors.
  • Elevated thymus chemokine CXCL7 levels were reduced by doxazosin exclusively in male rats.

Conclusions:

  • NAα1 receptor antagonism with doxazosin can ameliorate chronic inflammatory pain by reducing glial activation and restoring a more inhibitory noradrenergic tone.
  • Sex-specific effects on anxiety and cognitive behaviors highlight the complexity of the noradrenergic system and its modulation.
  • Findings suggest that targeting NAα1 receptors may shift the locus coeruleus's role from pain promotion to pain inhibition.